Research Article: Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
Abstract:
Background: The advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents. However, further research is required to better define its safety profile.
Introduction:
Objectives: To determine the cardiovascular toxicity of tisagenlecleucel in children and adolescents.
Read more